Mellstedt H[Author] - Search Results

Year	Number of Results
1972	1
1973	3
1974	5
1975	8
1976	9
1977	9
1978	8
1979	5
1980	8
1981	7
1982	12
1983	12
1984	10
1985	8
1986	7
1987	11
1988	16
1989	29
1990	16
1991	24
1992	7
1993	10
1994	9
1995	13
1996	10
1997	11
1998	9
1999	11
2000	7
2001	6
2002	11
2003	13
2004	13
2005	11
2006	14
2007	15
2008	11
2009	5
2010	3
2011	7
2012	8
2013	12
2014	9
2015	5
2016	5
2017	7
2018	5
2019	1
2020	2
2021	0

1

Therapeutic vaccines for cancer: an overview of clinical trials.

Melero I, Gaudernack G, Gerritsen W, Huber C, Parmiani G, Scholl S, Thatcher N, Wagstaff J, Zielinski C, Faulkner I, Mellstedt H. Melero I, et al. Among authors: mellstedt h. Nat Rev Clin Oncol. 2014 Sep;11(9):509-24. doi: 10.1038/nrclinonc.2014.111. Epub 2014 Jul 8. Nat Rev Clin Oncol. 2014. PMID: 25001465 Review.

2

Biosimilars - terms of use.

Declerck P, Mellstedt H, Danese S. Declerck P, et al. Among authors: mellstedt h. Curr Med Res Opin. 2015 Dec;31(12):2325-30. doi: 10.1185/03007995.2015.1098601. Epub 2015 Oct 27. Curr Med Res Opin. 2015. PMID: 26397731 Review.

3

The challenge of biosimilars.

Mellstedt H, Niederwieser D, Ludwig H. Mellstedt H, et al. Ann Oncol. 2008 Mar;19(3):411-9. doi: 10.1093/annonc/mdm345. Epub 2007 Sep 14. Ann Oncol. 2008. PMID: 17872902 Free article. Review.

4

Ibrutinib-A double-edge sword in cancer and autoimmune disorders.

Kokhaei P, Jadidi-Niaragh F, Sotoodeh Jahromi A, Osterborg A, Mellstedt H, Hojjat-Farsangi M. Kokhaei P, et al. Among authors: mellstedt h. J Drug Target. 2016;24(5):373-85. doi: 10.3109/1061186X.2015.1086357. Epub 2015 Sep 11. J Drug Target. 2016. PMID: 26362595 Review.

5

Glioblastoma-synthesized G-CSF and GM-CSF contribute to growth and immunosuppression: Potential therapeutic benefit from dapsone, fenofibrate, and ribavirin.

Kast RE, Hill QA, Wion D, Mellstedt H, Focosi D, Karpel-Massler G, Heiland T, Halatsch ME. Kast RE, et al. Among authors: mellstedt h. Tumour Biol. 2017 May;39(5):1010428317699797. doi: 10.1177/1010428317699797. Tumour Biol. 2017. PMID: 28459367 Free article. Review.

6

Cancer initiatives in developing countries.

Mellstedt H. Mellstedt H. Ann Oncol. 2006 Jun;17 Suppl 8:viii24-viii31. doi: 10.1093/annonc/mdl984. Ann Oncol. 2006. PMID: 16801336 Free article. Review.

7

Overcoming immunosuppressive mechanisms.

Widén K, Mozaffari F, Choudhury A, Mellstedt H. Widén K, et al. Among authors: mellstedt h. Ann Oncol. 2008 Sep;19 Suppl 7:vii241-7. doi: 10.1093/annonc/mdn459. Ann Oncol. 2008. PMID: 18790959 Free article. No abstract available.

8

Polymorphisms within methotrexate pathway genes: Relationship between plasma methotrexate levels, toxicity experienced and outcome in pediatric acute lymphoblastic leukemia.

Esmaili MA, Kazemi A, Faranoush M, Mellstedt H, Zaker F, Safa M, Mehrvar N, Rezvany MR. Esmaili MA, et al. Among authors: mellstedt h. Iran J Basic Med Sci. 2020 Jun;23(6):800-809. doi: 10.22038/ijbms.2020.41754.9858. Iran J Basic Med Sci. 2020. PMID: 32695297 Free PMC article.

9

Monoclonal antibodies in cancer therapy.

Mellstedt H. Mellstedt H. Curr Opin Immunol. 1989-1990;2(5):708-13. doi: 10.1016/0952-7915(90)90035-f. Curr Opin Immunol. 1989. PMID: 2701972 Review. No abstract available.

10

Monoclonal antibodies in human cancer.

Mellstedt H. Mellstedt H. Drugs Today (Barc). 2003;39 Suppl C:1-16. Drugs Today (Barc). 2003. PMID: 14988743 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results